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IRRITABLE BOWEL SYNDROME 
 
Irritable bowel syndrome (IBS), the prototypical functional GI disorder, is 
common throughout the world and often requires care from primary care and 
specialist physicians. Because no etiology is found with routine treatment testing, IBS 
is a symptom-based diagnosis, requiring chronic abdominal discomfort / pain and 
abnormal bowel function; other Gastrointestinal (GI) symptoms are also common. 
Though it is considered as a functional bowel disorder the burden of the disease to the 
patient is very high and the quality of life in patients with IBS is miserable. Once an 
IBS sufferer has told “some of my earliest memories are sitting in the back of a car in 
excruciating pain during family trips and not telling anyone” and such is the quality of 
life in patients with IBS. 
      IBS appear to be part of a continuum of GI and CNS (Central nervous system) 
reactions to external and internal stimuli. At one end of this spectrum, many people 
have functional GI symptoms in response to emotional stress. Many such individuals 
do not seek health care for these symptoms, yet others have severe symptoms with or 
without stress that impair their quality of life. In the absence of a biological marker, 
defining abnormality on the spectrum ranging from occasional, stress related GI 
symptoms in people not seeking care to disabling symptoms in patients with refractory 
IBS is controversial.  
 
 
Definition: 
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Various criteria’s are used to define IBS which includes Manning criteria, 
Kruis criteria, Rome I criteria and the Rome II criteria.(1,2) The latest and the most 
widely used criteria at present is the Rome III criteria which defines IBS as shown in 
the Table 1.(3) 
Rome III Criteria for Irritable bowel syndrome (IBS) 
Recurrent abdominal pain or discomfort** at least 3 days/month in the last 
3 months associated with two or more of the following: 
1. Improvement with defecation 
2. Onset associated with a change in frequency of stool 
3. Onset associated with a change in form (appearance) of stool 
* Criterion fulfilled for the last 3 months with symptom onset 
at least 6 months prior to diagnosis 
** “Discomfort” means an uncomfortable sensation not described as pain. 
 
Table 1: Rome III criteria for IBS 
 
Mechanism of disease : 
A number of different mechanisms have been implicated in the pathogenesis of 
IBS, including abnormal motility, visceral hypersensitivity, low-grade inflammation, 
and stress. Genetic factors could modulate the processing of gastrointestinal signals 
centrally and the inflammatory and immune responses locally, possibly predisposing 
to IBS. It seems reasonable to postulate that for IBS to manifest, several 
abnormalities—multiple hits—might need to occur. The most prominent symptoms in 
IBS are pain, discomfort, and bloating, which involve interpretation at a cortical level 
of signals originating in the gut (Brain gut axis) (Fig1, 2). It seems likely that in IBS, 
an understanding of the individual, including his or her psychosocial nature and 
response to environmental factors, influences the expression of any biological 
determinants (Fig.3). (4)  
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Figure 1: Afferent pathway of Brain gut axis 
 
 
           
Figure 2: Efferent pathway of brain gut axis 
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Figure 3: Pathogenesis of IBS 
 
Mechanism and possible treatments therefore can be considered according to 
the level at which signaling becomes abnormal, starting at the level of the gut and 
finishing in the secondary association areas of the cerebral cortex (Box 1) 
Box 1: Mechanisms & Treatment of IBS 
Level Mechanism Possible treatments 
Gut lumen Physical / chemical stimulation by 
food, gas 
Dietary, antibiotics, prebiotics 
Gut mucosa Inflammation, altered afferent 
signaling (enteroendocrine, mast cells) 
Anti inflammatory, mast cell 
stabilizers ,probiotics 
Spinal cord  Central sensitization  NMDA antagonists  
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Role of Probiotics : 
It has been suggested that the colonic flora could be abnormal in a subset of 
patients with IBS, resulting in increased colonic fermentation, production of excess 
gas, and development of symptoms.(5) This has led to an interest in pre- and probiotic 
therapy for IBS. Probiotics are defined as preparation of alive microorganisms of 
specific genus and species in sufficient numbers to alter the microflora (by 
implantation or colonization) and by doing so exert beneficial effects in the host. 
           The clear delineation of a postinfective variety of IBS, and the description in 
numerous studies of evidence of low grade inflammation and immune activation in 
IBS, suggest a role of a dysfunctional relationship between the indigenous flora and 
the host in IBS. Accordingly, this provides a clear rationale for the use of probiotics in 
this disorder especially the post infectious variety of IBS. Other modes of action, 
including bacterial displacement and alterations in luminal contents, are also plausible. 
Clinical evidence of efficacy remains scanty, and a review of available trails, while 
providing some hints of efficacy and therapeutic promise, emphasizes the importance 
of clear definition of strain, selection, dose and viability. Therefore this study is 
undertaken to determine the role of probiotics in IBS.  
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AIM 
 
 
 
The aim of our study is to evaluate the role of probiotics in Irritable bowel syndrome. 
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REVIEW OF LITERATURE 
 
IBS is a clinical syndrome in which chronic abdominal discomfort or pain 
occur with disturbed bowel habit not explained by an established organic or 
biochemical abnormality.(6)The definition of IBS has evolved from a diagnosis of 
exclusion to making a confident positive diagnosis based on standard criteria which at 
present is the Rome III criteria (Table ). (3) 
Manning Criteria* ( BOX:2) 
    Abdominal pain eased after bowel movement 
    Looser stools at onset of abdominal pain 
    More frequent bowel movements at onset of abdominal pain 
    Abdominal distension 
    Mucus per rectum 
    Feeling of incomplete emptying 
* Diagnostic cut-off: three or more of the six symptoms listed.
 
                                                      
Kruis Criteria (BOX:3) 
Patient's History 
    Abdominal pain 
    Flatulence 
    Irregularity of bowel movements
    Symptoms more than 2 years 
    Mixed diarrhea and constipation
    Pellet-like stools or mucus 
 
Physician's Assessment†  
    Abnormal physical findings 
    Erythrocyte sedimentation rate >20 mm/2 hr 
    Leukocytosis (>10,000 cm3) 
    Haemoglobin (female <12 g/dL; male <14 g/dL) 
   
 History of blood in stool 
 
† If any abnormal physical findings or any of the laboratory parameters assessed by 
the physician are present, IBS is excluded. 
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Previous criteria’s includes Manning criteria, Kruis criteria, Rome I and Rome 
II criteria (Box 2, 3). (1, 2) 
 
Epidemiology : 
IBS is one of the most common occurrences in OP medicine and the most 
frequent reason for consultation with a gastroenterologist. (7) Because a limited 
proportion of subjects suffering from IBS seek medical for this condition, only tip of 
the iceberg is exposed and knowledge of IBS epidemiology depends on research in 
the general population to estimate the disease burden and to plan management and 
public health interventions. (7)   
 
IBS affects approximately 3% - 15% of the general population based on 
various diagnostic criteria. There seem to be differences in disease epidemiology 
between the eastern and the western world. As data from larger Asian epidemiological 
studies begin to surface, however, such differences appear to be less marked. The 
proportion of IBS patients who consult a physician for their symptoms is around 50%. 
Psychological factors and the presence and duration of abdominal pain are all 
significant predictors for health care seeking. 
 
 Natural history and risk factors : 
IBS is characterized by fluctuation of symptoms, sometimes between the 
different bowel subtypes, and by periods of symptom remission. (8) Unnecessary 
abdominal surgery is performed in a high proportion of IBS sufferers.  
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Risk factors : 
IBS is a multifactorial condition in which GI motor and sensory dysfunction 
and psychological traits may contribute, in combination with a series of environmental 
factors such as acute GI infections and food intolerance. There also may be a 
background genetic predisposition. (9)  Research on classical risk factors such as 
smoking and alcohol consumption has shown no association. (10)  Along with the 
established role for psychosocial conditions in IBS, other risk factors are emerging. 
Evidence for post infectious IBS is mounting, but the clinical usefulness of 
characterizing such patients remains unclear. Food sensitivities are frequently present 
in IBS, but more well conducted trials of avoidance diets and desensitization are 
needed. Finally, genetic markers in IBS are an increasing focus of attention, but the 
amount of phenotypic variance explained by genetic variability remains to be 
established.  
Pathophysiology : 
The precise pathophysiology of IBS remains unknown. (11) For some time, 
pathophysiological and pharmacological research efforts have focused on 2 principal 
targets: dysmotility and altered visceral sensation. (12)  There is no doubt that IBS is 
associated with several disturbances in motor function, not only in the colon, but 
throughout the GI tract, as reflected by the former use of such terms as spastic colon 
or spastic colitis to describe this syndrome and by the continued emphasis on the use 
of antispasmodics in its therapy. (13)  Although it remains likely that dysmotility, or 
spasm, may play a role in the precipitation of symptoms, the specificity of any 
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proposed motor phenomenon for IBS has been questioned, and the primacy of 
dysmotility in the pathogenesis of IBS is now in doubt. Visceral hypersensitivity 
usually demonstrated by assessing the response to balloon inflation in the rectum or 
elsewhere, is a common phenomenon in IBS. and in all functional GI disorders, 
including functional dyspepsia and noncardiac chest pain. (14)  Visceral 
hypersensitivity and related phenomena, such as visceral hyperalgesia and abnormal 
central perception, are so common in IBS that visual hypersensitivity, elicited by 
inflation of a rectal barostat balloon in the rectum, has been proposed as a diagnostic 
test for IBS. (14)   Akin to the situation with dysmotility, the specificity of this 
phenomenon for IBS has been questioned; some experts in the field contend that 
visceral hypersensitivity reflects the impact of psychological traits associated with, or 
consequent upon, IBS and that it is not, therefore, a fundamental pathophysiological 
mechanism in IBS. (15)   
 
More recently, roles for enteric infection and intestinal inflammation have been 
proposed. Thus, retrospective and prospective studies have documented the new onset 
of IBS following bacteriologically confirmed bacterial enteritis and others have 
provided evidence of low-grade mucosal inflammation and immune activation in 
patients who have IBS. (16, 17, 18, 19, 20))   The enteric flora also have been implicated; 
there has been a suggestion that some patients who have with IBS may harbor 
bacterial overgrowth and that their symptoms may be ameliorated by its eradication. 
(21)   Despite these observations, the ever increasing understanding of gut flora-mucosa 
interaction and the existence of a significant body of basic research to support a role 
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for inflammatory and immune processes in contributing to enteric neuromuscular 
dysfunction, the role of lumen-mucosa interactions, in IBS, remains largely 
unexplored. It is in this content that probiotics have come to be evaluated in the 
management of IBS.  
 
Why use probiotics in IBS? 
Antibacterial and antivial effects : 
Many probiotic organisms exert antibacterial and antiviral effects and could, 
therapy, prevent or modify the course of postinfective IBS. (22)  Probiotics have been 
shown to be beneficial for preventing such human diarrheal conditions as toddlers 
`diarrhea and clostridium difficile-related, antibiotic associated diarrhea. (22)   
 
These effects could be especially relevant to postinfectious IBS. Real data are 
beginning to emerge that directly support the concept of post infective or post 
dysenteric IBS. In a retrospective analysis, Mckendrick and Read reported on 12 
patients (out of 38) who developed chronic bowel dysfunction within 12 months of 
documented salmonella gastroenteritis. (16)  Taking advantage of the presence of 
centralized public health microbiology laboratories in the UK, Neal and colleagues 
performed a retrospective analysis on a large group of patients who had documented 
bacterial gastroenteritis. (23)  When followed 6 months later, 7% had developed 
symptoms consistent with IBS. They went on to identify the following risk factors for 
post infectious IBS: being female and having a prolonged initial illness. Another 
study, also from UK, included 318 patients with gastroenteritis followed for 1 year. (24)  
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This study included a control population drawn from a national database. The rate of 
new diagnosis of IBS during the 12-months period of study was 4.4% for those with 
prior exposure to gastroenteritis and 0.3% for the control group, with a relative risk for 
developing IBS after gastroenteritis in excess of 10. Recent prospective studies have 
clarified the concept of post infectious IBS future. The first included 75 patients with 
acute gastroenteritis who were followed for at least 6 months. (25)  At 3 months, 22 had 
developed IBS. Similar risk factors were identified female gender and a prolonged 
episode of gastroenteritis. In addition, they noted that the patients who developed IBS 
had higher scores for anxiety, depression, somatization and neurosis. They also 
provided some insights into the natural history of this disorder. At 6 months, 91% had 
persistent symptoms, at 9 months 79% had persistent symptoms and at 12 months 
75% had persistent symptoms, suggesting that many of these individuals truly had 
developed chronic IBS. A second study from the same group evaluated 94 patients 
with acute gastroenteritis, and a control group, at the onset of the symptoms of GE and 
3 months later with a questionnaire, psychometric testing, flexible sigmoidoscopy 
(with biopsy), whole gut transit study, and rectal distension. (26)   They carefully 
excluded all patients with prior GI dysfunction, something that had not always been 
done in other studies. At 3 months, 23% of the gastroenteritis group had developed 
IBS.  
 
Again 64% of those who developed postinfectious IBS were female. 
Psychological factors again proved predictive of IBS risks. Recent experience of a 
major life event and a high hypochondriasis score were especially predictive for 
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developing postinfectious IBS.   For the first time, this study explored the possible role 
of inflammation. At the onset of gastroenteritis, 37% had evidence of microscopic 
colitis, regardless of whether they subsequently went on to develop IBS. At 3 months, 
in contrast, an increase in the number of chronic inflammatory cells was seen only 
among the patients who had developed IBS. In a very recent study, another group 
demonstrated a persisting increase in rectal mucosal enteroendocrine cells, T 
lymphocytes and in gut permeability in patients who had postdysenteric IBS. (27)   
Finally, an innovative, intriguing study surveyed individuals about to travel abroad to 
high-risk areas for enteric infections before travel, immediately on return, and at least 
12 weeks later. (28)   Forty-six percent developed traveler’s diarrhea. At 12 weeks, 
9.5% had new-onset IBS by Rome criteria, a relative risk of about 7, very consistent 
with other studies. Although probiotics have not been evaluated in the context of 
postinfectious IBS, the ability of probiotic preparations to influence the outcome of 
bacterial infections, such as Clostridium difficile colitis, and viral infections, such as 
rotavirus diarrhea, and the experimental demonstration of bactericidal, toxin-
neutralizing and antiviral effects for specific probiotic strains, suggest that probiotics 
may have a role for preventing on treating postinfectious IBS.  
 
Anti-inflammatory effects : 
IBS also may be associated with inflammation or immune activation in the 
absence of an infectious trigger. That inflammation could lead to altered enteric nerve 
or muscle function had been demonstrated in the past in such disorders as Chagas’ 
disease and postviral gastroparesis. IBS-type symptoms also have been associated 
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with inflammatory bowel disease (IBD) and celiac disease, even when in apparent 
remission. (29)  More direct and compelling evidence recently was provided by 
Chadwick and colleagues, who evaluated 77 patients who had IBS, of whom 55% 
would be considered as diarrhea-predominant; none had a confirmed infectious origin 
for their IBS. (18)   All had colonic biopsies taken for conventional histology and 
immunohistology. Thirty-eight had normal histology; 31 demonstrated microscopic 
inflammation, and eight fulfilled criteria for lymphocytic colitis. Among the group 
with normal histology, however, immunohistology revealed increased intraepithelial 
lymphocytes, and an increase in CD3 + and CD25 + cells in the lamina propria. All, 
therefore, showed evidence of immune activation. These features were even more 
evident in the microscopic inflammation group. These patients additionally revealed 
increased neutrophils, mast cells, and natural killer cells. All of these 
immunopathological abnormalities were most evident in the lymphocytic colitis 
group. These patients also demonstrated HLA-DR staining in crypts and increased 
CD8+cells in the lamina propria. Taking the group of IBS patients as a whole, CD3+ 
cell numbers were higher among those with diarrhea than among alternators or those 
with predominant constipation. In contrast, among the noninflamed IBS group, the 
presence of mast cells was a predictor of constipation. Surprisingly, given the 
described direct relationship between symptoms and chronic inflammation among 
patients who have postinfectious IBS, these authors did not find an association 
between the nature of disease onset or disease duration and immunological findings. 
That patients who have IBS may be predisposed to an inflammatory response to 
luminal triggers is also supported by the finding of a reduced frequency of the high-
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producer phenotype for the anti-inflammatory cytokine interleukin (IL)-10 among 
patients who have IBS. (20)   Most recently, among a group of 78 unselected IBS 
patients, the authors demonstrated in peripheral blood mononuclear cells an alteration 
in the ratio between the cytokines IL-10 and IL-12. this became skewed toward a Th1, 
proinflammatory profile. (19)   
 
Although the inflammatory hypothesis in IBS is in its infancy, there is already 
some evidence for the extension of the inflammatory process beyond the confines of 
the mucosal compartment. Tornblom and colleagues addressed this issue in 10 
patients who had severe IBS by examining full-thickness jejunal biopsies obtained at 
laparoscopy. (30)   In nine patients, they found low-grade infiltration of lymphocytes in 
the myenteric plexus; four of these had an associated increase in intraepithelial 
lymphocytes, and six patients demonstrated evidence of neuronal degeneration. Nine 
patients had longitudinal muscle hypertrophy, and seven patients had abnormalities in 
the number and size of interstitial cells of Cajal. Three of their patients reported an 
acute onset of their IBS; in two patients, this possibly was precipitated by 
gastroenteritis. The finding of intraepithelial lymphocytosis is consistent with the 
reports of Chadwick and colleagues in the colon and of Wahnschaffe and colleagues 
in the duodenum. (18)   
 
A direct linkage between immune activation and symptoms has been provided 
by the work of Barbara and colleagues, who demonstrated, not only an increased 
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prevalence of mast cell degranulation in the colon in IBS, but also a direct correlation 
between the proximity of mast cells to neuronal elements and pain severity. (31)   
 
What is the pathogenesis of these inflammatory changes in IBS? With regard to 
postinfectious IBS, Spiller proposed that the development of chronic inflammation 
could represent a response to an initial bacterial infection among individuals rendered 
susceptible by a relative deficiency of anti-inflammatory cytokines. (32)  A similar 
hypothesis has been advanced to explain inflammation and immune activation in IBS, 
in general, where a failure to adequately down-regulate a proinflammatory response 
following a precipitating event (eg, GI infection) may sustain the IBS state. (19, 20)   
Why than does this inflammatory response not progress to the state of florid 
inflammation so characteristic of IBD? In this regard, Collins suggests that the 
prominence of CD25+cells in the inflammatory infiltrate, as reported by Chadwick 
and colleagues, may act to prevent progression to a more florid inflammatory 
response. (17)    
 
Laboratory experiments repeatedly have demonstrated the anti-inflammatory 
effects of certain probiotics. For example, oral administration of a Bifidobacterium 
exerted a profound anti-inflammatory effect in the IL-10 knock-out mouse, a potent 
model of IBD that was associated with suppression of the proinflammatory cytokines 
IFNγ, tumor necrosis factor (TNF)-α, and IL-12, while preserving activity of the anti-
inflammatory cytokine TGFβ. (33)  Others have demonstrated similar effects for the 
probiotic cocktail VSL #3 in another animal model of colitis; in this instance, the anti-
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inflammatory effect was evident with bacterial DNA alone. In clinical practice, 
probiotics have been demonstrated to prevent development of pouchitis and reduce the 
relapse rate of this condition following successful antibiotic treatment. (34, 35)   By 
reducing mucosal inflammation, probiotics could decrease immune mediated 
activation of enteric motor and sensory neurons and modify neural traffic between the 
gut and the central nervous system. (34, 35, 36)   There is some preliminary evidence that 
probiotic administration may diminish visceral hypersensitivity in animal models. (36)   
Furthermore, effects on motility and perception could go some way toward explaining 
the beneficial effects of probiotics on bloating, given current concepts on the roles of 
altered gas transit and visceral hypersensitivity in the pathogenesis of this symptom. 
 
Most recently, a probiotic bacterium, lactobacillus paracasei, has been shown 
to reverse changes in intestinal muscle function induced by inflammation consequent 
upon infection of an animal model with Trichinella spiralis. (36)   This latter finding 
indicates that a luminally administered probiotic can influence inflammatory 
processes beyond the mucosal surface.  
 
In a recent study by Eammon Quigley , which compared the effects of two 
probiotics, a Lactobacillus and a Bifidobacterium, in IBS, efficacy was observed with 
the Bifidobacterium alone. Bifidobacterium, but not the Lactobacillus or placebo, 
normalized the disturbed cytokine ratio, providing, for the first time in people, 
evidence for an association between an effect on an inflammatory process and 
amelioration of symptoms. (19)    
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Altering the composition of the gut flora : 
Although the status of the gut flora in IBS remains a source of some 
controversy, probiotic-related changes in the enteric flora could influence gut function 
either directly, through the augmentation of commensal lactobacilli or Bifidobacteria 
or the elimination of pathogens, or indirectly, through a reduction in pathogen-related 
inflammation or bacterial fermentation. (11)   Whether IBS is accompanied by 
quantitative or qualitative changes in the bacterial flora of the small or large intestine 
remains a contentious issue. Although some have described bacterial over growth in 
the small intestine and qualitative alterations in the fecal flora and increased bacterial 
fermentation, others have failed to replicate these findings. (11, 38, 39)   A reduction in 
bacterial fermentation by a modulation of the composition of the flora could 
contribute to the alleviation of the gas-related symptoms common in IBS and that 
appear to reflect a selective defect in intestinal gas transport. An effect on bloating 
may be the most consistent effect of probiotics across all studies.  
 
Effects on luminal contents : 
Probiotics could alter the volume or composition of stool and gas or increase 
intestinal mucus secretion. (40)   These effects could influence intestinal handling and 
thus modulate such symptoms as constipation and diarrhea. Of these putative effects 
of probiotics, an effect on stool bulking would appear unlikely, given the findings of 
the Eammon Quigley study of a Bifidobacterium in IBS. (19)   In contrast to the effects 
observed with two newly approved therapies for IBS, namely alosetron and tegaserod, 
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Eammon Quigley failed to observe any change in stool consistency or frequency. (41, 42)   
This apparent independence of the effects of Bifidobacterium from any change in 
stool frequency or form implies that this therapeutic approach may be applicable to all 
patients who have IBS, irrespective of stool pattern.  
 
Effects on gut flora and luminal contents are not mutually exclusive and could 
interact with other factors known to influence symptom onset in IBS. Bacterial 
overgrowth or qualitative changes in the gut flora with a shift toward more gas-
producing organisms could interact with unabsorbed carbohydrates (such as in the 
patient with lactase deficiency or fructose intolerance) to increase colonic 
fermentation, which could, not only increase intestinal gas-related symptoms, but also 
affect function in the proximal gut by promoting gastroesophageal reflux and 
modifying proximal gastric relaxation. These latter effects could contribute to the 
overlap between IBS and other functional GI disorders such as nonerosive 
gastroesophageal reflux disease and functional dyspepsia. 
Metabonomic understanding of probiotic effects in humans with irritable bowel 
syndrome: 
Systematic effect of probiotics on inflammatory bowel disease through metabonomics 
approach has been extensively studied to date and metabonomic characterization of 
the probiotics effect on IBS is also needed for better understanding the effect with 
respect to host metabolic mechanism. In a study done by Hong et al seventy-four IBS 
patients meeting Rome criteria were randomized to receive probiotics and placebo 
through a parallel-group, double-blind, randomized, placebo-controlled clinical study. 
(43)  Probiotic fermented milk and placebo was administered 3 times daily for 8 weeks. 
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Fecal counts of the Lactobacilli, but not Bifidobacteria species, which included in the 
probiotic milk, were increased significantly in feces of IBS patients receiving 
treatment (P=0.014). Nuclear Magnetic resonance (NMR) data set coupled with 
multivariate statistical analysis identified intrinsically elevated serum levels of glucose 
(P=0.0265) and tyrosine (P=0.0016) in IBS patients. These levels normalized to those 
of healthy individuals in the probiotic administration group, but not the placebo group. 
They concluded that in a subset of IBS patients there exists a potential dysregulation 
in energy homeostasis (serum glucose) and liver function (serum tyrosine) that may be 
improved through probiotics supplementation 
 
Studies of probiotics in irritable bowel syndrome: 
Numerous studies have evaluated the response of IBS to probiotic preparations 
and, while results between studies are difficult to compare because of differences in 
study design, probiotic dose, and strain, there has been some evidence of symptom 
improvement. The overall impact of probiotics, in IBS, remains unclear. In a recent 
review, Hamilton-Miller, while drawing attention to the shortcomings of prior trails in 
terms of study design, concluded that there was overall sufficient evidence of efficacy 
to warrant further evaluation. (44)   Most studies reviewed were small and almost 
certainly underpowered to demonstrate anything other than a very striking benefit. 
Several did not verify bacterial transit and survival by confirmatory stool studies. 
Many different organisms and strains were employed, and dosage varied from as little 
as 105 to 1013. Furthermore, some, including a very recent study, employed probiotic 
cocktails rather than single isolates, rendering it impossible to induce wheat were the 
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active moieties. Nevertheless, some positive results were noted. Niedzielin reported 
resolution of abdominal pain in all 20 patients treated for 4 weeks with L plantarum 
299V, in contrast to only 11 of 20 patients who received a placebo. (45)  Halpern and 
colleagues noted a significant reduction in an IBS symptom index with a capsule 
containing 5x109 heat-killed L acidophilus. (46)    O’Sullivan and colleagues, while 
failing to detect an effect of L casei GG on overall symptomatology, did note a trend 
toward reduction in bloating. (47)    Nobaek and colleagues, employing L plantarum, 
described a similar benefit in terms of relief of bloating, as did Kim and colleagues in 
their evaluation of VSL # 3. (48,49)     
The effects of two probiotic strains on symptoms in patients who had IBS was done 
by O’Mahony et al and he demonstrated superiority for a B longum infantis over 
Lactobacillus or placebo for each of the cardinal symptoms of the IBS (abdominal 
pain/discomfort, distension/bloating, and difficult defection), and for a composite 
score. (50)  For each individual symptom, with the notable exceptions of bowel 
movement frequency and consistency, the group randomized to B infantis experienced 
a greater reduction in symptom scores during the treatment period.  These 
symptomatic benefits were associated with parallel trends in quality of life. 
Furthermore, this therapy was tolerated well and free of significant adverse events. As 
these benefits were observed independent of any change in stool frequency or form, 
they cannot be attributed to either a laxative or an antidiarrheal effect. Although this 
study did not involve a comparison with any other therapeutic modality, and the study 
design differed, in some aspects, from recent large trials of serotonergic agonists and 
antagonists, the therapeutic gain observed for Bifidobacterium over placebo (20% to 
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25%) was certainly no less than that reported for tegaserod and alosetron (10% to 
20%). This study with B longum therefore provides clear evidence for a benefit, in 
IBS, for a clearly defined single-organism probiotic preparation and suggests that 
some strains may be more effective that others for this indication. This was a 
relatively small pilot study, and its findings must be interpreted with caution. Large, 
randomized controlled trials of this Bifidobacterium strain, however, are warranted in 
IBS, and detailed explorations of its mechanism(s) of action are indicated.  
     Saggiaro A et al in 2004 showed that combination strain of Lactobacillus 
plantarum and Lactobacillus acidophilus improved overall symptom score in ROME 
II criteria IBS patients. (51)     
      O`Mahony et al in 2005 showed that either Bifidobacterium infantis or 
Lactobacillus salivarius improved the quality of life assessment using an IBS specific 
questionnaire in ROME II criteria IBS patients. (50)     
       Kajender K et al in 2005 showed that Lactobacillus rhamnosus ,Bifidobacterium, 
Propionibacterium improved abdominal pain, distension, flatulence and borborygmi in 
ROME I&II criteria IBS patients.(52)     
       Bausserman M et al in 2005 showed that lactobacillus caused changes in 
abdominal pain severity in ROME II criteria IBS patients. (53)     
       Whorwell PJ et al in 2006 showed that Bifidobacterium .infantis caused 
improvement of abdominal pain/discomfort, bloating/distension in ROME II criteria 
IBS patients. (54)     
     Gawronska A et al in 2007 showed that Lactobacillus rhamnosus GG caused 
improvement of abdominal pain in children   with   ROME II criteria  
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IBS. (55)     
   Guyonnet et al in 2007 showed the beneficial effect of a probiotic food on 
discomfort health related quality of life score and bloating in IBS-C and on stool 
frequency in ROME II criteria constipation predominant IBS patients. (56)     
    Jong et al in October 2008 showed that treatment with probiotics significantly 
reduced the mean global IBS scores compared with baseline scores in IBS-D patients. 
(57)     
   Williams EA et al in Jan 2009 showed that multistrain probiotic preparation LAB4 
caused statistically greater improvement in the symptom severity score of IBS and in 
the scores for quality of life days with pain and bowel habit in ROME II criteria IBS 
patients. (58)     
   Hong KS et al in June 2009 showed that probiotics caused significant decrease in 
abdominal pain, defecation discomfort, and sum of scores in ROME III criteria IBS 
patients. (59)     
   Dolin BJ in December 2009 showed that Bacillus coagulans significantly decreased 
average number of bowel movements per day in IBS patients. (60)     
   Hun L in March 2009 showed that Bacillus coagulans caused statistically significant 
improvement from baseline abdominal pain and bloating scores in IBS patients. (61)     
  Enck P et al in Feb 2009 showed that E.coli caused statistically significant 
improvement in general symptom score and abdominal pain in IBS patients when 
given for 8 weeks. (62)     
     Lyra et al in 2010 showed that probiotic supplement exert specific alterations in 
IBS associated microbiota. (63)     
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     Guandalini S et al in 2010 showed that VSL#3 is superior to placebo in the 
subjective assessment of relief of symptoms, abdominal pain, bloating and family 
assessment of life disruption in IBS patients. (64)     
Choi SC, Kim BJ et al in 2011 showed that probiotics had additive benefit for the 
symptoms of constipation in IBS-C group patients. They used a combination of 
Streptobacillus thermophilus,Lactobacillus acidophilus and Bifidobacterium infantis. 
(65)     
Choi et al in 2011 showed that Sacch.boulardii given for 4 weeks in IBS-D/mixed 
type improved quality of life. (66)     
 Guglielmetti S et al in 2011 showed that probiotics alleviated global IBS and 
improved IBS symptoms simultaneously with an improvement of quality of life and 
Bifidobacterium bifidum was used as the probiotic. (67)     
     Sondergaard B et al in 2011 showed in IBS ROME II criteria patients that 
probiotics improved symptom score during the study period but no improvement was 
seen at the end of the study period. (68)     A combination of Lactobacillus paracasei, 
Lactobacillus acidophilus and Bifidobacterium lactis was used as a probiotic in the 
above mentioned study 
 
Indian scenario: 
Only epidemiological studies are available from India and there are no studies 
regarding the effect of probiotics in IBS.  A prospective multicentre study in which 
data was obtained from 30 centers from all over the country with many authors 
contributing to the study compiled by Udhay Ghosal et al showed that symptom 
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complex suggestive of IBS was seen in 4.2% of community subjects.(69)     In that 
study, IBS-Indeterminate type (57.18%) was the most common followed by IBS-C 
(38.97%) and then followed by IBS-D (3.84%). IBS was common in middle aged 
male patients (39.4yrs) according to that study. 
Need for Indian study on role of probiotics in IBS: 
More than 18 Randomized controlled studies have evaluated the effect of probiotics 
on various symptoms in patients with IBS. Few studies have also evaluated the effect 
of probiotic on Quality of life of patients with IBS. The results are very much 
conflicting between each trial so that the exact role of probiotic in IBS patient is not 
known. Almost all of the studies are from outside India and there are no studies in 
Indian population. Considering the pathophysiology of IBS where the cultural, 
economic, religious and social activities plays a major role, there may be considerable 
difference between the disease profile between Indian population and foreign 
population. Hence a randomized controlled study in Indian population is required to 
confirm the role of probiotics in Indian patients with IBS 
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MATERIALS AND METHODS 
 
Patients with Irritable bowel syndrome fulfilling the Rome III Criteria (Table: 2) 
attending the outpatient department of the Department of Medical Gastroenterology 
were included in the study. Patients with red flag signs (Table: 3), those who are 
already on probiotics and those who are not willing for the study are excluded from 
the study .Ethical clearance was obtained from the ethical committee. A written 
informed consent was obtained from all the patients entering the study. (See 
Appendix) The study is a prospective single blind randomized controlled study. 
 
Rome III Criteria for Irritable bowel syndrome (IBS) 
Recurrent abdominal pain or discomfort** at least 3 days/month in the last 
3 months associated with two or more of the following: 
1. Improvement with defecation 
2. Onset associated with a change in frequency of stool 
3. Onset associated with a change in form (appearance) of stool 
* Criterion fulfilled for the last 3 months with symptom onset 
at least 6 months prior to diagnosis 
** “Discomfort” means an uncomfortable sensation not described as pain. 
 
Table 2 
 
 
Red flag symptoms: 
Unintentional weight loss                                                       
Loss of appetite                                                                        
Short duration of symptoms                                             
Nocturnal symptoms                                                       
Rectal bleeding                                                                     
Awareness of lump in the abdomen                                 
Perianal mass/ discharging sinuses                                  
Fever                                                                                        
 
Table 3 
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Detailed analysis of their symptoms were recorded including assigning a symptom 
score for each symptom.(See Proforma in the Appendix)  
The symptom score is graded as follows: 
      Mild -          No impairment of daily activities 
      Moderate – Impairment of daily activities but able to carry activities 
      Severe –    Not able to carry daily activities (Absent to work/School) 
Quality of life was also assessed with Health, wellness and quality of life 
questionnaire (See Appendix).  Routine investigations which includes complete blood 
count, urine routine, motion routine, blood sugar were done in all patients.ECG was 
done in all older patients. 
The patients were divided into 3 groups based on the type of IBS as follows, 
Group 1: IBS-D (Diarrhea predominant IBS) 
Group 2: IBS-C (Constipation predominant IBS) 
Group 3: IBS-M  (Mixed diarrhea and Constipation). 
Each group was randomized to receive either Probiotic (Probiotic group) or placebo 
(Placebo group) for a period of 6 weeks. The Probiotic used and its composition is 
shown in Table 4.   
 
Strain Strength 
Streptococcus faecalis JPC 30 million
Clostridium butyricum 2 million 
Bacillus mesentericus JPC 1 million
Lactobacillus sporogenes 50 million 
Table 4 : Composition of Probiotic used. 
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Probiotic was given in a twice a day dosage. The placebo used was vitamin capsule in 
the same twice a day dosage. At the end of 6 weeks the symptom score and Quality of 
life score were recorded again for both Probiotic and placebo groups and the data were 
analyzed to find out any statistical significance (Master chart in the Appendix) 
 
Statistical analysis: 
Unpaired t test was used to find out whether the age distribution and sex 
distribution was equally comparable between the probiotic group and the placebo 
group. Fischer exact test was used to calculate the p value for improvement in 
symptoms between the probiotic group and the placebo group 
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OBSERVATION AND RESULTS 
 
Total of 113 patients entered the study.65 patients had IBS-D (57.5%),  43 patients 
had IBS-C (38%) and 5 patients had IBS-M (4.5%) (Figure: 4). There were 72 (64%) 
male patients and 41 (36%) female patients in the study. The mean age of patients in 
the study was 38.94 yrs (19-72yrs). (BOX: 4) 
IBS-D:                                               BOX:4 
No of cases:        65(57.5%) 
Mean age:           38.33 
Males:                 40(61.5%) 
Females:             25(39.5%) 
IBS-C 
No of cases:        43(38%) 
Mean age:           41.67 
Males:                 28(65%) 
Females:             15(35%) 
IBS-M: 
No of cases:        5(4.5%) 
Mean age:           29.2 
Males:                 4(80%) 
Females:             1(20%) 
IBS in general (IBS-D+IBS-C+IBS-M) 
No of cases:        113 
Mean age:           39.2 
Males:                 72(64%) 
Females:             41(36%) 
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                                                         Figure: 4 
 
In the IBS-D group there were 40 (61.5%) males and 25 (39.5%) females (Figure: 4). 
In the IBS-C group there were 28 (65%) males and 15 (35%) females (Figure: 4). In 
the IBS-M group there were 4 (80%) males and only one(20%) female though the 
incidence of this group is very low. There were 9 dropouts in the study, 5 in the IBS-D 
group and 4 in the IBS-C group. Out of 113 patients 104 (92%) completed the study. 
The compliance of the patients who completed the study was good. 
 
 
113 patients entered the study 
IBS-D:65(57.50%) IBS-C:43(38.05% IBS-M:5(4.45%) 
Probiotic: 
33 patients 
Placebo: 
32 patients 
Probiotic: 
22 patients 
Placebo: 
21 patients 
Probiotic: 
3 patients 
Placebo: 
2patients 
30 
completed 
30 
completed 
20 
completed 
19 
completed 
3 completed 
 
2 completed 
 
104 completed the study out of 113 (92%) 
3 dropouts 2 dropouts 2 dropouts 2 dropouts 
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IBS-D Group: 
 
IBS-D was the most common form of IBS type in the study and constituted 57.5% (65 
out of 113) of total cases. The frequency of stools in this group ranged from 2 to 15 
times per day in the study, but most of the patients had 4-7 stools/day (51 pts out of 65 
which constituted 78.5% of cases) (Table 5).  9 patients had less than 4 stools per day 
(13.8%) only 5 patients had more than 8 times per day (7.7%).The abdominal 
pain/discomfort was mild in 52 cases (80%) and moderate in 13 cases (20%) and none 
of the patient had severe pain/discomfort. Bloating was seen in 39 cases (60%), 24 
patients in the probiotic group and 15 in the placebo group. Overall quality of life 
(QOL) assessment score was 2 (unhappy) in 14 cases (21.5%), 3 (mostly unsatisfied) 
in 45 cases (69.2%) and 4 ( Mixed)  in 6 cases(9.3%).Other associated symptoms like 
nausea, heartburn, regurgitation, feeling of indigestion, was seen in 11 patients (17%). 
Urinary symptoms were seen in one patient in the form of urgency and incontinence 
occasionally. 
                      In this group 33 received probiotic and 32 received placebo out of which 
30 in probiotic and 30 in placebo subgroup completed the study. The age and sex 
distribution between the probiotic and placebo group was statistically comparable. 
Frequency of stools improved in 16 out of 30 (53.33%) in the probiotic group and 7 
out of 30 (23.33%) in the placebo group and the p value was significant (0.03) (Table 
6 & Chart 1). The abdominal pain/discomfort improved in 15 out of 30 (50%) in 
probiotic group and 8 out of 30 (26.6%) in placebo group and the p value was not 
significant (0.11). (Table 6 & Chart 1). Bloating improved in 14 out of 24 (58.3%) in 
probiotic group and 5 out of 15 (33.3%) in placebo group and the p value was not 
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significant (0.19) (Table 7 and chart 2). The QOL improved in 15 out of 30 (50%) in 
probiotic and 8 out of 30 (26.67%) in placebo and the p value was not significant 
(0.11) (Table 6 & chart1)     
 
 
 
   Frequency of stools:  
     
 
 
 
 
   Abdominal pain/Discomfort: 
Severity No of patients Percentage
Mild 52 80%
Moderate 13 20%
Severe 0 0
    
   Bloating: 
 No of cases Percentage 
Bloating 39  60% 
No bloating 26 40% 
    
  Quality of Life (QOL): 
Grade No of patients Percentage 
2 (Unhappy) 14 21.50% 
3 (Mostly dissatisfied) 45 69.20% 
4 (Mixed) 6 9.30%
 
Frequency No of patients Percentage 
4-7/day 51 78.50% 
<4/day 9 13.80%
>8/day 5 7.70% 
Table 5: Symptomatology of patients in IBS-D group 
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 Probiotic  Placebo P value 
No of cases 30 30  
Improvement in 
frequency of stools 
16(53.33%) 7(23.33%) 0.03(significant) 
Improvement in 
abdominal pain 
15(50%) 8(26.67%) 0.11(Not significant)
Improvement in QOL 15(50%) 8(26.67%) 0.11(Not significant)
 Table 6: Effect of probiotic vs placebo in IBS-D group. 
 
 
 
 
                   
                       Chart 1 Effect of probiotic vs placebo in IBS-D pts 
                                          Key: Imp-Improvement 
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Bloating Probiotic group Placebo group 
Improvement in bloating 14 5 
No Improvement in 
bloating 
10 10 
Table 7: Improvement in bloating with probiotic vs placebo,   
p value is 0.19 
 
 
 
 
 
 
 
 
 
                    
                    
                 Chart 2 Effect of probiotic vs placebo on bloating in IBS-D pts  
                                          Key: Imp-Improvement 
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IBS-C group: 
 
IBS-C constituted 38% of cases (43 cases out of 113). Patients with IBS passed stools 
mostly once in 2-3 days (40 out of 43 i.e. 93%).3 patients were passing stools once in 
4-5 days (7%). Abdominal/Discomfort was mild in 35 pts (81.40%) and moderate in 8 
patients (18.60%) and none of the patient had severe symptom. Bloating occurred in 
31 patients (72%). The overall Quality of life assessment score was 2 (unhappy) in 8 
patients (18.60%), 3 (Mostly dissatisfactory) in 34 patients (79%) and 4 (mixed) in 1 
patient (2.40%) (Table 8). Associated symptoms like nausea, heartburn, belching, 
feeling of indigestion and regurgitation was seen in 7 patients (16.30%). 
                    In IBS-C group 22 received probiotic and 21 received placebo out of 
which 20 in probiotic and 19 in placebo completed the study. The age and sex 
distribution between the probiotic and placebo group was statistically comparable. 
Improvement in frequency of stools was seen in 5 out of 20 patients (25%) in 
probiotic group and 4 out of 19 patients (21%) in the placebo group and p value was 
not significant (1.00)( Table 9 & Chart 3). The abdominal pain/Discomfort improved 
in 12 out of 20 patients (60%) in probiotic group and 5 out of 19 patients (26.30%) in 
placebo group and the p value was not significant (0.0536). ( Table 9 & Chart 3) 
Improvement in bloating was seen in 11 out of 16 patients (68.75%) in the probiotic 
group and 4 out of 15 patients (26.67%) in placebo group and the p value was 
significant (0.03) (Table 10 & Chart 4). The overall QOL assessment score 
improvement was seen in 13 out of 20 patients (65%) in the probiotic group and 5 out 
of 19 patients (26.67%) in the placebo group and the p value was significant (0.02). 
(Table 9 & Chart 3). 
36 
 
 
   Frequency of stools:  
     
 
 
 
 
   Abdominal pain/Discomfort: 
Severity No of patients Percentage
Mild 35 81.40%
Moderate 8 18.60%
Severe 0 0
    
   Bloating: 
 No of cases Percentage 
Bloating 31 72% 
No bloating 12 28% 
    
  Quality of Life (QOL): 
Grade No of patients Percentage 
2 (Unhappy) 8 18.60% 
3 (Mostly dissatisfied) 45 79% 
4 (Mixed) 6 2.4%
 
Frequency No of patients Percentage 
1/2-3days 40 93% 
1/4-5days 3 7%
Table 8: Symptomatology of IBS-C patients 
 Probiotics Placebo P value 
No of cases 20 19  
Improvement in 
frequency of stools 
5(25%) 4(21%) 1.00 (Not 
Significant) 
Improvement in abd pain 12(60%) 5(26.30%) 0.0536(Not 
Significant) 
Improvement in QOL 13(65%) 5(26.30%) 0.02(Significant) 
Table 9: Effect of probiotic vs placebo in IBS-C patients 
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Chart 3 Effect of probiotic vs placebo in IBS-C patients 
                                          Key: Imp-Improvement 
 
 
 
 
Bloating Probiotic group Placebo group 
Improvement in bloating 11 4 
No Improvement in 
bloating 
5 11 
Table 10: Improvement in bloating with probiotic vs placebo,  
p value is 0.03 
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chart 4 Effect of probiotic vs placebo on bloating in IBS-C patients 
Key: Imp-Improvement 
 
 
 
 
 
 
IBS-M: 
The IBS-M constituted only 4.45% of cases (5 out of 113). 3 patients received 
probiotic and 2 received placebo.2 out of 3 patients in the probiotic group showed 
improvement in symptoms while none of the patients in the placebo group showed 
any improvement in the symptoms; however statistical significance could not be 
calculated because of very small sample size. 
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DISCUSSION 
EPIDEMIOLOGY AND CLINICAL PROFILE: 
In our study IBS-D was the most common form of IBS which accounts for 57.5% of 
cases followed by IBS-C which accounts for 38% and then followed by IBS-M which 
accounted for only 4.5% of cases. In a study by Katsenilos et al in Greece, out of 373 
patients with IBS 136 (36.5%) suffered from diarrhoea-predominant IBS, 165 (44.2%) 
suffered from IBS-C and 72 (19.3%) suffered from mixed type IBS.(70) This difference 
would probably be due to the fact that in even normal patients, the number of stools 
per week is less in the western population when compared to the east probably due to 
the difference in the dietary habits between the west and the east. Our data was also 
totally different from previously published Indian data on IBS done by the Task force 
of Indian society of Gastroenterology where IBS-Indeterminate type (57.18%) was the 
most commonest followed by IBS-C(38.97%)and then followed by IBS-D(3.84%).(68)  
The study was a prospective multicentre study in which data was obtained from 30 
centers from all over the country with many authors contributing to the study 
compiled by Udhay Ghosal et al. In that study among indeterminate type constipation 
predominant was 53% and diarrhea predominant was 47%. Hence if we take that in to 
account again IBS-C was the most common type in that study which was again not 
found in our study. This difference might probably be due to difference in the clinical 
profile of IBS within different parts of the country. Population group in our study 
were only from southern part of India but the study by Udhay et al was from 30 
centers all over the country, and in India we know that the diet, culture, religion, 
socioeconomic status are different in different parts of the country and they  play an 
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important role in pathophysiology of IBS. We are continuing a larger study on this 
aspect and once the results are available we may be able to confirm our findings. 
The incidence of IBS was more common in middle aged male patients in our study in 
contrast to the finding in other parts of the world where it is common in females. But 
this was also noted in the Indian study published by Udhay Ghosal et al where IBS 
was common in middle aged male patients (39.4yrs).In our study the mean age of 
presentation in male patients is 36.84 years and in female patients it is 43.34 years. 
Male to female ratio was 1.75: 1.00 in our study but in the Indian study by Udhay et al 
the ratio was 2.12:1.00. 
       Among the associated symptoms bloating was the most common symptom which 
was seen in 70 out of 113 patients (62%). Bloating was more common in IBS-C (72%) 
than IBS-D (60%) in our study. Other associated symptoms include nausea, heartburn, 
regurgitation, feeling of indigestion, urinary symptoms which were seen in 20 out of 
113 cases (17.70%).This data was low when compared to the other previous studies 
(25-50%). 
Effect of Probiotics on IBS: 
More than 18 Randomized controlled studies has evaluated the effect of probiotics on 
various symptoms in patients with IBS. Few studies have also evaluated the effect of 
probiotic on Quality of life of patients with IBS. The results are very much conflicting 
between each trial so that the exact role of probiotic in IBS patient is not known. 
Almost all of the studies are from outside India and there are no studies in Indian 
population. Considering the pathophysiology of IBS where the cultural, economic, 
religious and social activities plays a major role, there may be considerable difference 
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between the disease profile between Indian population and foreign population. Hence 
a randomized controlled study in Indian population is required to confirm the role of 
probiotics in Indian patients with IBS. We selected frequency of stools, abdominal 
pain and bloating as main symptoms to be compared between probiotic and placebo 
since most of the studies have shown improvements with these symptoms. We also 
evaluated the improvement in quality of life in patients treated with probiotics which 
only very few studies have done. 
 
IBS-D Population: 
In our study the improvement with stool frequency was found to be statistically 
significant with probiotic when compared to placebo (p value is 0.03). This result was 
consistent with previous studies by O Sullivan et al (Lactobacillus GG 1 × 1010 
cfu/day given two tablets twice a day for 20 week),Dolin BJ et al (Ganeden BC 30 
bacillus coagulans given  once a day for 8 weeks) and Guglielmetti S et al 
(Bifidobacterium bifidum MIMBb75 given once a day for 4 weeks).The  studies done 
by Choi et al (Saccharomyces boulardii  given for 4 wks) and Anwarul Kabir 
(Lactobacillus casei strain GG did not show any significant improvement in frequency 
of stools with probiotics when compared to placebo . 
           We also observed that improvement in frequency of stools was mostly seen in 
patients with more than 5 stools per day (p value is 0.02) showing that probiotics are 
more useful when stool frequency is more than 5 times per day. The cumulative 
reduction in stool frequency was atleast 2 stools/day. 
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         The improvement in abdominal pain was not statistically significant with 
probiotics when compared to placebo in patients with IBS-C ( p value was 0.11).This 
was also noted by the study done by Choei et al (Saccharomyces boulardii  given for 4 
wks).However the studies done by Guglielmetti S et al (Bifidobacterium bifidum 
MIMBb75 given once a day for 4 weeks),Jeng et al (Streptobacillus thermophilus, 
Lactobacillus bulgaricus, l.acidophilus, Bifidobacterium longus), Kim HJ et al (VSL # 
3 mixture of bacteria combination One packet twice a day 8 wks), and O Sullivan et 
al (Lactobacillus GG 1 × 1010 cfu/day given two tablets twice a day for 20 week) 
showed that the improvement  in  abdominal pain was significant with probiotics 
when compared to placebo. Though many previous studies have shown that 
abdominal pain improves significantly with probiotics when compared to placebo our 
study failed to show any significant benefit. 
        The improvement in bloating was also not significant in probiotics when 
compared to placebo in patients with IBS-C. Similar result was seen in the study by 
Choi et al but most other studies (Guglielmetti S et al, Jeng et al, Kim HJ et al, O 
Sullivan et al) showed significant improvement with probiotics when compared to 
placebo). 
   In our study the overall QOL did not improve significantly with probiotics when 
compared to placebo (p value was 0.11) i patients with IBS-C. This was also seen in 
the study by Simren et al 2010 (L.Paracasei’ L.acidophilus, Bifidobacterium lactis). 
Thus in our study though probiotic improved the frequency of stools significantly it 
failed to show any significant improvement in abdominal pain, bloating and overall 
Quality of life when compared to placebo. 
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IBS –C Population: 
In our study 39 patients with IBS-C completed the study, 20 in the probiotic group and 
19 in the placebo group. The improvement in the frequency of stool was not 
significant between probiotic and placebo group in our study (p value was 1.00). 
Similar result was also seen in the study by Sondergaard B et al (1.Lactobacillus 
paracasei ssp paracasei F19, 2.Lactobacillus acidophilus La5 and 3.Bifidobacterium 
lactis Bb12 given for 8 weeks). However Guandalini S et al jul 2010 in their study 
showed a significant improvement in stool frequency with probiotic (VSL# 3 given 
for 6 weeks) when compared to placebo. The probable reason for the improvement 
would be the strain used in that study and we need to confirm this by doing more 
stdies with VSL#3. In a study done by Chois et al, probiotics in combination with 
dietary fibre increased the frequency of stool in patients with IBS-C when compared 
to probiotic given alone. However the result of the above test has to be interpreted 
carefully as dietary fibre may itself independently increase the stool frequency even 
without the use of probiotic along with it. So there are conflicting results in the 
previous studies with regard to improvement in stool frequency and our study also 
failed to show any significant improvement with probiotics in patients with IBS-C. 
        The improvement in abdominal pain was also not significant with probiotics 
when compared to placebo (p value was 0.056) in our study but p value was almost 
very close to being significant (<0.05 when compared to 0.056).However many of the 
previous studies showed significant improvement in abdominal pain with probiotics 
when compared to placebo. Only in the study by Gayonet et al there was no 
significant improvement in the abdominal pain. Hence even though many studies 
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showed that the abdominal pain improves significantly with probiotics, our study did 
not show any statistical significance. 
   Probiotics improved bloating significantly in patients with IBS-C when compared to 
placebo in our study (p value was 0.03). Previous studies done by Guyonnet et 
al,Whorewell et al, Kajander K et al, Kim et al 2003, Kim et al 2005, Niedzelin K et 
al, Nobaeks et al, O Sullivan et al, Gade et al and  many others also showed clearly the 
benefit of probiotic in IBS-C patients with bloating when compared to placebo. Hence 
our study is also consistent with the observations of the previous studies that 
probiotics are useful in IBS-C patients with bloating when compared to placebo. 
    The Quality of life in patients also improved with probiotics in our study when 
compared to placebo (p value was 0.02). Previous studies which showed similar 
results include the one done by Guyonnet et al, O Mahony et al, Niv et al and 
Guglielmetti et al. The quality of life improvement was more in patients with bloating 
mainly due to the improvement of their bloating symptom which was more 
troublesome to the patients.  
IBS-M Population: 
 There were only 5 patients with IBS-M (Mixed) in our study. It constituted only 4.5% 
of patients with IBS when compared to 19% in a study by Katsenilos et al in Greece 
and 57.18% ( IBS-Indeterminate variety) in a study by Uday et al from India. Three 
patients received probiotics and two patients received placebo in this group. 2 out of 3 
patients in the probiotic group showed improvement in symptoms while none of the 
patients in the placebo group showed any improvement in the symptoms. However 
because of the very small sample size we were not able to compare the results. Not 
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many studies have concentrated on this group of IBS patients. With  more 
understanding of Irritable bowel syndrome and with formation and subsequent 
modification of guidelines (Recently Rome III) we are able to categories IBS patients 
in to either diarrhoea predominant (IBS-D) or constipation predominant most of the 
time and only few patients are left with indeterminate variety which are categorized as 
IBS-M (Mixed).   
 
 
Limitations of the study:  
The strains used in our study were not used by any of the previous studies mentioned 
above and hence it is difficult for us to compare the effect of the strains used in our 
study with the results of other studies since the strains were different. 
         Since we know that IBS mainly depends on the psychosocial, economical, 
cultural, and religious, dietary aspects of the population under study, it is very difficult 
for us to compare our results with other studies because all of them are outside India 
and the population is totally different. We need Indian studies for comparison as well 
as for confirmation our results.    
                  The effect of probiotics is mainly assessed based on the subjective 
improvement of the patient which again can be considered one of the limitations of 
our study. 
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CONCLUSION 
 
In patients with constipation predominant IBS (IBS-C), probiotics improves bloating 
and quality of life (QOL) when compared to placebo, however the improvement in 
abdominal pain and frequency of stools was not significant. 
 
In patients with diarrhea predominant IBS (IBS-D), probiotics improves the frequency 
of stools when compared to placebo but the improvement in abdominal pain, bloating 
and quality of life was not significant. 
 
Hence from our study we conclude that probiotic treatment have a definitive role in 
the constipation predominant IBS patients with bloating and in reducing the stool 
frequency in diarrhea predominant IBS with high frequency of stool passage (>5 
stools/day). 
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APPENDIX I 
 
CONSENT FORM AND 
PATIENT INFORMATION FORM 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
PATIENT CONSENT FORM 
Study Details  :  Role of Probiotics in Irritable Bowel Syndrome 
 
Study Centre :  Department of Gastroenterology, 
Madras Medical College, Chennai. 
Patient may check (3) these boxes 
I confirm that I have understood the purpose of procedure for the above study. I 
have the opportunity to ask question and all my questions and doubts have been 
answered to my complete satisfaction. 
 
I understand that my participation in the study is voluntary and that I am free 
to withdraw at any time without giving reason, without my legal rights being 
affected. 
 
I understand that sponsor of the clinical study, others working on the sponsor's 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and 
any further research that may be conducted in relation to it, even if I withdraw 
from the study I agree to this access. However, I understand that my identity 
will not be revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any data or 
results that arise from this study. 
 
I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms. 
 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological, biochemical, radiological tests. 
 
 
I hereby consent to participate in this study. 
 
 
Signature/ Thumb Impression: 
Patient Name and Address:   Place   Date 
 
 
 
Signature of Investigator 
Study Investigator’s Name:            Place   Date 
INFORMATION SHEET 
 
 We are conducting an randomized double blined controlled study on “The role 
of probiotics in Irritable Bowel Syndrome” at Department of Gastroenterology, 
Madras Medical College and Government General Hospital, Chennai. 
 The purpose of the study is to evaluate the the role of probiotics in Irritable 
Bowel Syndrome. 
 Irritable Bowel Syndrome patients will be divided into two groups. One group 
will received probiotics and other goup will receive placebo twice a day for six 
weeks. At the end of six weeks the effect of both the drugs on each of the 
symptoms will be analysed and compared. 
 Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
 The results of the special study may be intimated to you at the end of the study 
period or during the study if anything is found abnormal which may aid in the 
management or treatment. 
 
 
Signature of investigator Signature of participant 
Date: 
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PROFORMA 
 
 
 
 
 
 
 
 
APPENDIX: II 
PROFORMA 
Name  :                                                                         MGE NO: 
Age/ Sex:                                                                      IP NO:                                                               
Ocupation: 
Address: 
Chief complaints: 
History of presenting illness: 
Onset:                                  SUDDEN ( Following an AGE ) / GRADUAL 
Symptoms                           symptom scorebefore trt           Symp score after trt 
1.Abd pain/ 
 Abd discomfort 
2.Bloating/ 
Abd distension 
3.constipation: 
  a.straining 
  b.Incomplete evacuation 
  c.frequency 
  d.digital evacuation 
4.Loose stools: 
   a.Frequency 
  b.mucus 
  c.Urgency 
  d.incontinence 
5.flatulence: 
6.Borborygmi: 
7.nausea 
8.dyspepsia 
9.heartburn 
10. Regurgitation 
Other Non GI symptoms: 
Headache, Backache, Myalgia                                              YES/NO 
Urinary symptoms,Insomnia                                                  YES/NO 
History of red flag symptoms: 
Unintentional weight loss                                                       YES/NO 
Loss of appetite                                                                      YES/NO 
Short duration of symptoms                                                   YES/NO 
Nocturnal symptoms                                                               YES/NO 
Rectal bleeding                                                                       YES/NO 
Recent use of antibiotics                                                         YES/NO 
Awareness of lump in the abdomen                                        YES/NO 
Perianal mass/ discharging sinuses                                        YES/NO 
fever                                                                                         YES/NO 
Other relevant history: 
Relation to food : milk/ alcohol/ wheat etc.. 
Recent travel history 
Abnormal eating habits 
PAST HISTORY: 
History of DM/ HTN /TB/ BA/ IHD/ CVA/ EPILEPSY 
h/o similar illness in the past 
h/o surgery/ Jaundice/ transfusion/ Tatooing 
Personal history: 
H/o alcohol intake 
h/o smoking 
h/o psychiatric illness 
Family history: 
h/o GI cancers/ Inflammatory bowel disease/ celiac disease 
Examination: 
Pallor/ cyanosis/ Clubbing / Pedal edema/ Raised JVP/ Icterus/ Lymphadenopathy 
Ht:             Wt:                BMI: 
Oral cavity: 
AbdomenExamination: 
Inspection: 
Palpation: 
Percussion: 
Auscultation: 
Per rectal Examination: 
 
 
 INVESTIGATIONS 
CBC: 
Hb: 
TC: 
DC: 
ESR: 
PLT: 
Peripheral smear: 
RFT:   Urea: 
          Creatinine: 
Urine routine: 
Motion routine: 
CXR: 
ECG: 
USG ABDOMEN: 
FOS/COLONOSCOPY: 
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